Market revenue in 2021 | USD 109.5 million |
Market revenue in 2032 | USD 270.2 million |
Growth rate | 8.6% (CAGR from 2021 to 2032) |
Largest segment | Monoclonal antibodies |
Fastest growing segment | Thymectomy |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2032 |
Quantitative units | Revenue in USD million |
Market segmentation | Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy |
Key market players worldwide | AstraZeneca PLC, Grifols SA Ordinary Shares - Class A, Avadel Pharmaceuticals PLC, Novartis AG ADR, Pfizer Inc, AbbVie Inc, Roche Holding AG, GlaxoSmithKline, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to myasthenia gravis treatment market will help companies and investors design strategic landscapes.
Monoclonal antibodies was the largest segment with a revenue share of 64.29% in 2021. Horizon Databook has segmented the Spain myasthenia gravis treatment market based on cholinesterase inhibitors, chronic immunomodulators, monoclonal antibodies, rapid immunotherapies, thymectomy covering the revenue growth of each sub-segment from 2018 to 2032.
According to Global Competitiveness Report 2020 , the World Economic Forum placed Spain as the nation with one of the most well-established healthcare systems in Europe. The Spanish healthcare system offers its citizens both public and private healthcare alternatives.
The National Health System, managed by the Spanish Ministry of Health, is responsible for developing policies and maintaining national health budget. It provides free healthcare services to anyone living and working in Spain.
The country’s supportive healthcare policies and initiatives to increase public awareness and monitor disease occurrence rate are expected to increase the demand for MG therapies in the market.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain myasthenia gravis treatment market , including forecasts for subscribers. This country databook contains high-level insights into Spain myasthenia gravis treatment market from 2018 to 2032, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account